‘Thriving research and innovation partnerships will benefit people in the UK and India and beyond.’
The UK and India have established five joint research projects to tackle antimicrobial resistance (AMR). The total investment is £8 million, with the UK contributing £4 million from the UK Research and Innovation Fund for International Collaboration. India is matching this with its own resources. The UK is India’s second biggest research partner.
India is a major producer of antimicrobials in the pharmaceutical industry global supply chain and the research projects aim to develop a better understanding of how waste from antimicrobial manufacturing could be inadvertently fuelling AMR. The projects could lead to important advances in the global fight against antibiotic resistance.
Subject to clearance, the five projects will begin during September 2020. The projects will cover a number of areas with collaborations between universities and institutions from both countries. Projects include: Resolving the fate and studying the impact of pharmaceutical wastes on the environment and local community of a pharmaceutical manufacturing hub. Teams from the University of Warwick, UK, PGIMER, CSIR-NEERI, Aligarh Muslim University, Indian Institute of Technology Delhi and Banaras Hindu University, will collaborate to inform policy makers, implementers and industry experts and managers, to understand the impacts of inappropriate waste disposal.
Lord Tariq Ahmad of Wimbledon, Minister of State for South Asia and the Commonwealth said ‘The UK has already partnered with India’s Serum Institute to manufacture the vaccine for Covid-19, if clinical trials are successful, [there are] plans to distribute to a billion people across the developing world. But there is more we can do together to tackle urgent global health issues in the world. Our thriving research and innovation partnerships will benefit people in the UK and India and beyond.’